Our unique approach
Our protected enzyme particle can be further functionalized to provide specific targeting. In the case of digestive therapies, a muco-adhesive coating has been applied to the particles, which provides a 3-time longer residence time in the small intestine. Together with a sustained activity, this results in high efficacy and no pill burden.
Safe – The enzyme particles do not cross the intestinal epithelium; they remain fully non-systemic. Also, they do not accumulate in the GI tract as they are eliminated together with the mucus they are bound to and end up in the feces.
We have prioritized our enzymes for digestive therapies. Nevertheless, the platform can be applied more generally for metabolic therapies. We have generated in vitro efficacy and safety data in onco-metabolism showing great benefits of the platform against cancer cells. Data has also been acquired for systemic Enzyme Replacement Therapies (ERTs). The company is open to partnering for the joint development of innovative therapies in these areas.